DNMT3A and acute myeloid leukemia: We also observed systematic differences considering the percentage of peripheral blood blasts, white blood cell counts, platelet counts, and the hemoglobin level indicating that differentiation capabilities of AML cells with R882 and non-R882 DNMT3A mutations may differ at least to some extent (Supplementary Fig. 4).